Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Akhil Patel

Internal Medicine Holiday, FL Medical Doctor

NPI 1457617714 CMS profile 1364361

2254 US Highway 19, Holiday, FL 34691

Open in the dashboard

General payments

$7,074

100 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Akhil Patel of Holiday, FL is reported in the CMS Open Payments database as having received $7,074 across 100 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 92nd percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,001 11
2024 General $674 15
2023 General $2,727 40
2022 General $2,253 21
2021 General $358 12
2019 General $60 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Akhil Patel
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Akhil Patel were reported at $1,001. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Akhil Patel Internal Medicine median Middle half National median
2019 $60 $159 $48–$570 $163
2020 $0 $119 $33–$402 $114
2021 $358 $135 $37–$521 $132
2022 $2,253 $141 $42–$496 $149
2023 $2,727 $149 $45–$519 $160
2024 $674 $154 $47–$537 $164
2025 $1,001 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Merz North America, Inc. $3,100 14 payments
  2. AbbVie, Inc. $2,297 50 payments
  3. Allergan Inc. $1,146 25 payments
  4. Exelixis Inc. $175 1 payment
  5. Janssen Pharmaceuticals, Inc $133 1 payment
  6. Astellas Pharma US Inc $88 4 payments
  7. Abiomed $60 1 payment
  8. Novo Nordisk Inc $26 1 payment
  9. Corcept Therapeutics $17 1 payment
  10. Amgen Inc. $17 1 payment
  11. Other $15 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $5,668 82 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $1,406 18 payments
Products named General payments · program years 2019–2025
  1. BOTOX $1,810 41 payments
  2. Xeomin musculoskeletal $1,169 6 payments
  3. Xeomin Dermatology $1,076 2 payments
  4. CABOMETYX $175 1 payment
  5. XARELTO $133 1 payment
  6. Veozah $60 3 payments
  7. Impella $60 1 payment
  8. MYRBETRIQ $28 1 payment
  9. Ozempic $26 1 payment
  10. RYBELSUS $26 1 payment
  11. Other $52 3 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Billing to Medicare

Part B · data year 2024 · 7 billing codes

Paid by Medicare

$27,595

Medicare's payments for the services billed

Medicare patients

36

Average age 67

Services billed

340

15 women, 21 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Heart failure 61%
Diabetes 58%
Atrial fibrillation 53%
Chronic kidney disease 53%
COPD 47%
Depression 47%
Ischemic heart disease 44%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

1 product · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
BOTOX
  • AbbVie, Inc. $50
$50 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

100 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record